Assertion: inhaled nitric oxide | /r/HasProperty | ino
Facets:
Source sentences:
text: This release includes forward-looking statements concerning inhaled nitric oxide ("iNO") and the Company's iNO product, including statements with regard to the clinical data generated in the study described above.
text: GENOSYL DS, an innovative tankless delivery system for inhaled nitric oxide (iNO) was used by Stanford Medicine clinicians via telemedicine for outpatient, at-home treatment of a patient with pulmonary hypertension complicated by COVID-19, according to a case report published online on May 5, 2020 in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary and critical care medicine.
text: ATLANTA, May 6, 2020 /PRNewswire/ -- GENOSYL DS, an innovative tankless delivery system for inhaled nitric oxide (iNO) was used by Stanford Medicine clinicians via telemedicine for outpatient, at-home treatment of a patient with pulmonary hypertension complicated by COVID-19, according to a case report published online on May 5, 2020 in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary and critical care medicine.
text: ATLANTA, May 6, 2020 /PRNewswire/ -- GENOSYL DS, an innovative tankless delivery system for inhaled nitric oxide (iNO) was used by Stanford Medicine clinicians via telemedicine for outpatient, at-home treatment of a patient with pulmonary hypertension complicated by COVID-19, according to a case report published online on May 5, 2020 in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary and critical care medicine.
text: Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone.
text: This release includes forward-looking statements concerning inhaled nitric oxide ("iNO") and the Company's iNO product, including statements with regard to the clinical data generated in the study described above.
text: GENOSYL DS, an innovative tankless delivery system for inhaled nitric oxide (iNO) was used by Stanford Medicine clinicians via telemedicine for outpatient, at-home treatment of a patient with pulmonary hypertension complicated by COVID-19, according to a case report published online on May 5, 2020 in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary and critical care medicine.
text: Inhaled nitric oxide (iNO) is used to treat disorders of the pulmonary vasculature such as forms of PAH.
text: ATLANTA, May 6, 2020 /PRNewswire/ -- GENOSYL DS, an innovative tankless delivery system for inhaled nitric oxide (iNO) was used by Stanford Medicine clinicians via telemedicine for outpatient, at-home treatment of a patient with pulmonary hypertension complicated by COVID-19, according to a case report published online on May 5, 2020 in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary and critical care medicine.